Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01139333
Recruitment Status : Completed
First Posted : June 8, 2010
Last Update Posted : May 18, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.

Condition or disease Intervention/treatment
Leukemia Genetic: gene expression analysis Genetic: western blotting Other: flow cytometry Other: laboratory biomarker analysis

Detailed Description:


  • To evaluate Mer and Axl expression in samples from pediatric patients with acute myeloid leukemia (AML).
  • To determine if abnormal expression of Mer and Axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of AML in these patients.

OUTLINE: This is a multicenter study.

Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.

Study Type : Observational
Estimated Enrollment : 52 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples
Study Start Date : September 2009
Actual Primary Completion Date : May 2016

Primary Outcome Measures :
  1. Expression of Mer and Axl
  2. Association of abnormal expression of Mer and Axl with induction failure or relapse

Biospecimen Retention:   Samples With DNA
blood and tumor samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosis of acute myeloid leukemia


  • Diagnosis of acute myeloid leukemia
  • Children Oncology Group (COG) patient samples


  • Available clinical data


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01139333

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Kristen M. Eisenman, MD University of Colorado, Denver

Responsible Party: Children's Oncology Group Identifier: NCT01139333     History of Changes
Other Study ID Numbers: AAML10B4
COG-AAML10B4 ( Other Identifier: Children's Oncology Group )
CDR0000671452 ( Other Identifier: Clinical )
NCI-2011-02222 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: June 8, 2010    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016

Keywords provided by Children's Oncology Group:
childhood acute myeloid leukemia/other myeloid malignancies

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type